Old and New Treatment Options in IgA Nephropathy and Henoch Schönlein Purpura Nephritis/IgA Vasculitis in Children

被引:0
作者
Peruzzi L. [1 ,2 ]
Cocchi E. [1 ,2 ]
Tarizzo F. [1 ,3 ]
机构
[1] Pediatric Nephrology Unit, Regina Margherita Children’s Hospital, Piazza Polonia 94, Turin
[2] School of Pediatrics, University of Turin, Turin
[3] School of Pediatrics, Klinikum Fulda Department of Pediatrics, Fulda
关键词
Biomarkers; Corticosteroids; Henoch-Schönlein Purpura; IgA nephropathy; IgA vasculitis; Immunosuppression; Therapy;
D O I
10.1007/s40746-019-00168-1
中图分类号
学科分类号
摘要
Purpose of review: Henoch-Schönlein purpura nephritis (HSPN), known currently as nephritis associated with IgA vasculitis (IgAVN), and IgA nephropathy (IgAN) share pathogenetic mechanisms and almost indistinguishable histology, but have peculiar clinical behavior and outcome. Recent classifications, clinical trials, and discussions lead to critical revision of old and new treatments. Recent findings: In recent years, the histological classification of IgAN Oxford-MEST allowed the identification of histological and clinical risk factors for progression of IgAN and encouraged new studies to explore the value of different treatments, allowing a more standardized classification of enrolled patients. For HSPN, large clinical studies are lacking, and the old histological classifications available do not allow such a precise standardization. However, new efforts are made to follow the IgAN pipeline. Personalized therapies are being forecast, tailored according to histological and clinical risk factors implemented by more innovative biomarkers. The aim is to efficaciously treat both diseases in the earlier phases. The inflammatory process can be completely extinguished if treated adequately without delay, with a high percentage of permanent complete remission in children. Summary: The state-of-the-art knowledge of the elements useful to choose the appropriate treatment in HSPN/IgAVN and IgAN in children is reviewed. © 2019, Springer Nature Switzerland AG.
引用
收藏
页码:236 / 254
页数:18
相关论文
共 98 条
[1]  
Berger J., Hinglais N., Intercapillary deposits of IgA-IgG, J Urol Nephrol (Paris), 74, 9, pp. 694-695, (1968)
[2]  
Feehally J., Cameron J.S., IgA nephropathy: progress before and since Berger, Am J Kidney Dis, 58, 2, pp. 310-319, (2011)
[3]  
Levy M., Beaufils H., Gubler M.C., Habib R., Idiopathic recurrent macroscopic hematuria and mesangial IgA-IgG deposits in children (Berger’s disease), Clin Nephrol, 1, 2, pp. 63-69, (1973)
[4]  
Baart De La Faille-Kuyper E.H., Kater L., Kooiker C.J., Mees E.J.D., IgA-deposits in cutaneous bloodvessel walls and mesangium in Henoch Schoenlein syndrome, Lancet., 301, 7808, pp. 892-893, (1973)
[5]  
Faille-Kuyper E.H., Kater L., Kuijten R.H., Kooiker C.J., Wagenaar S.S., van der Zouwen P., Et al., Occurrence of vascular IgA deposits in clinically normal skin of patients with renal disease, Kidney Int, 9, 5, pp. 424-429, (1976)
[6]  
Davin J.-C., Ten Berge I.J., Weening J.J., What is the difference between IgA nephropathy and Henoch-Schö nlein purpura nephritis?, Kidney Int, 59, pp. 823-834, (2001)
[7]  
Komatsu H., Fujimoto S., Yoshikawa N., Kitamura H., Sugiyama H., Yokoyama H., Clinical manifestations of Henoch–Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR), Clin Exp Nephrol, 20, 4, pp. 552-560, (2016)
[8]  
Hwang H.H., Lim I.S., Choi B.S., Yi D.Y., Analysis of seasonal tendencies in pediatric Henoch-Schönlein purpura and comparison with outbreak of infectious diseases, Medicine (Baltimore), 97, 36, (2018)
[9]  
Singh S., Aulakh R., Kawasaki disease and Henoch Schonlein purpura: changing trends at a tertiary care hospital in north India (1993–2008), Rheumatol Int, 30, 6, pp. 771-774, (2010)
[10]  
Okubo Y., Nochioka K., Sakakibara H., Hataya H., Terakawa T., Testa M., Et al., Nationwide epidemiological survey of childhood IgA vasculitis associated hospitalization in the USA, Clin Rheumatol, 35, 11, pp. 2749-2756, (2016)